STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARTL
  4. [424B5] Artelo Biosciences, Inc. Prospectus Supplement (Debt Securities)

[424B5] Artelo Biosciences, Inc. Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ARTL logo
Artelo Biosciences Inc

NASDAQ:ARTL

ARTL Rankings

#10802 Ranked by Market Cap
N/A Ranked by Dividends

ARTL Latest News

Jul 9, 2025
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Jul 7, 2025
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
Jun 30, 2025
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Jun 26, 2025
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Jun 11, 2025
Artelo Biosciences Announces Reverse Stock Split

ARTL Latest SEC Filings

Jul 18, 2025
[8-K] Artelo Biosciences, Inc. Reports Material Event
Jul 11, 2025
[S-1] Artelo Biosciences, Inc. Files IPO Registration Statement
Jul 11, 2025
[8-K] Artelo Biosciences, Inc. Reports Material Event
Jul 9, 2025
[D] Artelo Biosciences, Inc. SEC Filing
Jul 7, 2025
[Form 4] Artelo Biosciences, Inc. Insider Trading Activity

ARTL Stock Data

15.58M
699.97k
0.82%
1.05%
0.04%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOLANA BEACH